Evidence map›Paper›PMID 33746537›Full record

ArticleSaudi journal of biological sciences2021

Validation and performance comparison of two SARS-CoV-2 IgG/IgM rapid tests.

Nisreen Naser Al Awaji, Hanadi Talal Ahmedah, Isra Mohammed Alsaady, Rowaedh Ahmed Bawaked, Mohammed A Alraey, Ahmed Ayed Alasiri, Abdullah Mofareh Alfaifi, Hamdan Ali Alshehri, Raed Alserihi, Elrashed B Yasin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Nisreen Naser Al AwajiDepartment of Health Communication Sciences, College of Health and Rehabilitation Sciences, Princess Nourah Bint Abdulrahman University, P.O Box 84428, Riyadh 11671, Saudi Arabia.
Hanadi Talal AhmedahDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Rabegh, Saudi Arabia.
Isra Mohammed AlsaadyDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Rowaedh Ahmed BawakedCentre of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Mohammed A AlraeyInfection Prevention and Control Department, King Abdullah bin Abdulaziz University Hospital, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Ahmed Ayed AlasiriDepartment of Pathology and Laboratory Medicine, Prince Mohammed Bin Abdulaziz Hospital, Riyadh, Saudi Arabia.
Abdullah Mofareh AlfaifiDepartment of Pathology and Laboratory Medicine, King Abdullah Bin Abdulaziz University Hospital, Riyadh, Saudi Arabia.
Hamdan Ali AlshehriDepartment of Pathology and Clinical Laboratory, King Abdullah Bin Abdulaziz University Hospital, Riyadh, Saudi Arabia.
Raed AlserihiDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Elrashed B YasinDepartment of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Rabigh, Saudi Arabia.
King Abdulaziz University · SAKing Abdulaziz Hospital · SAPrincess Nourah bint Abdulrahman University · SAPrince Mohammed bin Abdulaziz Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease called COVID-19. COVID-19 is primarily diagnosed using molecular techniques mainly real-time reverse transcriptase PCR. Reliable and accurate serologic assays for COVID-19, are an important tool for surveillance and epidemiologic studies. In this study, the IgG/IgM Rapid Test Cassette and the Prima COVID-19 IgG/IgM Rapid Test for the detection of SARS-CoV-2 antibodies in blood, serum and plasma samples collected from patients up to 48 days after symptom onset in Saudi Arabia were validated. Overall, both tests showed poor performance and cannot be utilised for COVID-19 diagnosis as a point of care test or to determine seroprevalence.

Indexed as

COVID-19COVID-19, Coronavirus disease 2019COVID-19 rapid testRT-PCR, real-time reverse transcription-polymerase chain reactionSARS-CoV-2 antibodiesSARS-CoV-2 IgGSARS-CoV-2 IgMSARS-CoV, severe acute respiratory syndrome coronavirusSerological test for COVID-19

Identifiers

PMID33746537
PMCPMC7955801
OpenAlexW3137842084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.